JAMA Oncology Author Interviews podcast

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

0:00
15:06
15 Sekunden vorwärts
15 Sekunden vorwärts

Weitere Episoden von „JAMA Oncology Author Interviews“